3Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America[J]. Clin Infect,Dis ,2000,30 (4) :696-709.
4Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years [J]. J Antimicrob Chemother,2006,57 (3) :384-410.
6Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy [J]. Transplantation, 2003,76 ( 11 ) : 1632-1637.
7Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial [ J]. Clin Infect Dis,2007,44( 1 ):2-12.
8Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy [ J]. Clin Infect Dis,2004,39( 11 ) :1563-1571.
9Denning DW, Man: KA, Lau WM, et al. Micafungin ( FK463 ) , alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis [ J]. J Infect ,2006,53 (5) :337-349.
10Ng TT, Denning DW. Liposomal amphotericin B ( AmBisome ) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data [ J]. Arch Intern Med, 1995,155 ( 10 ) : 1093-1098.
9Thomas JC, Madigan M. A retrospective study to evaluate a computer based model for amplifying early anti-fungal intervention and microbial detection of patients at risk for fungemia. San Antonio, TX: Seventh Annual Focus on Fungal Infections, 1997.
10Uzun O, Ascioglu S, Anaissie EJ, et al. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32(12)∶1713-1717.
